Incidence of blast phase in myelofibrosis according to anemia severity.

Autor: Mora B; Department of Oncology, ASST Sette Laghi Ospedale di Circolo Varese Italy., Maffioli M; Department of Oncology, ASST Sette Laghi Ospedale di Circolo Varese Italy., Rumi E; Department of Molecular Medicine University of Pavia Pavia Italy.; Hematology Fondazione IRCCS Policlinico San Matteo Pavia Italy., Guglielmelli P; Center of Research and Innovation of Myeloproliferative Neoplasms University of Florence Florence Italy., Caramella M; Hematology ASST Grande Ospedale Metropolitano Niguarda Milan Italy., Kuykendall A; Malignant Hematology Department, Blood and Marrow Transplantation H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA., Palandri F; Institute of Hematology 'Seràgnoli' IRCCS Azienda Ospedaliero-Universitaria di Bologna Bologna Italy., Iurlo A; Hematology Foundation IRCCS Ca'Granda Ospedale Maggiore Policlinico Milan Italy., De Stefano V; Hematology Fondazione Policlinico Universitario A. Gemelli IRCCS Rome Italy., Kiladjian JJ; Hôpital Saint-Louis Université Paris Cité Paris France., Elli EM; Division of Hematology and Bone Marrow Unit IRCCS San Gerardo dei Tintori Monza Italy., Polverelli N; Unit of Blood Diseases and Stem Cell Transplantation ASST Spedali Civili di Brescia Brescia Italy., Gotlib J; Division of Hematology, Stanford Cancer Institute Stanford University School of Medicine Stanford California USA., Albano F; Hematology - Department of Emergency and Organ Transplantation University of Bari Bari Italy., Silver RT; Richard T. Silver Myeloproliferative Neoplasms Center NewYork-Presbyterian Weill Cornell Medical Center New York New York USA., Benevolo G; Hematology Unit AOU Città della Salute e della Scienza di Torino Turin Italy., Ross DM; Haematology Directorate, SA Pathology Royal Adelaide Hospital Adelaide South Australia Australia., Devos T; Department of Hematology KU Leuven University Hospitals Leuven Leuven Belgium., Borsani O; Department of Molecular Medicine University of Pavia Pavia Italy.; Hematology Fondazione IRCCS Policlinico San Matteo Pavia Italy., Barbui T; FROM Research Foundation ASST Papa Giovanni XXIII Bergamo Italy., Porta MGD; Department of Biomedical Sciences Humanitas University Pieve Emanuele Italy., Bertù L; Department of Medicine and Surgery University of Insubria Varese Italy., Komrokji R; Malignant Hematology Department, Blood and Marrow Transplantation H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA., Vannucchi AM; Center of Research and Innovation of Myeloproliferative Neoplasms University of Florence Florence Italy., Passamonti F; Hematology Foundation IRCCS Ca'Granda Ospedale Maggiore Policlinico Milan Italy.; Department of Oncology and Haemato-Oncology University of Milan Milan Italy.
Jazyk: angličtina
Zdroj: EJHaem [EJHaem] 2023 Jul 17; Vol. 4 (3), pp. 679-689. Date of Electronic Publication: 2023 Jul 17 (Print Publication: 2023).
DOI: 10.1002/jha2.745
Abstrakt: Myelofibrosis (MF) is a clonal malignancy frequently characterized by anemia and in 10%-20% of cases it can evolve into blast phase (BP). Anemia in MF is associated with reduced survival and -in primary MF- also with an increased probability of BP. Conventional treatments for anemia have limited effectiveness in MF. Within a dataset of 1752 MF subjects largely unexposed to ruxolitinib (RUX), BP incidence was 2.5% patients per year (p-y). This rate reached respectively 4.3% and 4.5% p-y in case of patients with common terminology criteria for adverse events (CTCAE) grade 3/4 and grade 2 anemia, respectively, that represented together 32% of the cohort. Among 273 MF cases treated with RUX, BP incidence was 2.89% p-y and it reached 4.86% p-y in subjects who started RUX with CTCAE grade 2 anemia (one third of total). Within patients with red blood cell transfusion-dependency at 6 months of RUX (21% of the exposed), BP rate was 4.2% p-y. Our study highlights a relevant incidence of BP in anemic MF patients, with a similar rate whether treated with or without RUX. These findings will help treating physicians to make decisions on the safety profile of innovative anemia treatments.
Competing Interests: BM received honoraria for lecture from Novartis. FP received honoraria for lectures and advisory boards from Novartis, GSK, Bristol‐Myers Squibb/Celgene, Sierra Oncology, Abbvie, Janssen, Roche, AOP Orphan, Karyiopharma, Kyowa Kirin and MEI, Sumitomo. Other authors have no conflict of interest to disclose.
(© 2023 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: